Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$66.60 USD

66.60
1,644,379

+0.71 (1.08%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arpita Dutt headshot

Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo

by Arpita Dutt

A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.

    BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA

    by Zacks Equity Research

    BioMarin (BMRN) extended the review period of its biologics license application (BLA) for pegvaliase by three months to May 25, 2018.

      BioMarin's (BMRN) Gene Therapy Enters First Phase III Study

      by Zacks Equity Research

      BioMarin (BMRN) commences the first phase III study to evaluate the 6e13 vg/kg dose of its investigational gene therapy, valoctocogene roxaparvovec, for severe hemophilia A.

        Spark Therapeutics Stock Plunges on Hemophilia Therapy Data

        by Zacks Equity Research

        Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.

          BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%

          by Zacks Equity Research

          BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

            Here's Why Sarepta Stock is Up More Than 70% in 6 Months

            by Zacks Equity Research

            Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.

              Catalyst (CPRX) Reports Positive Phase III Data on Firdapse

              by Zacks Equity Research

              Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.

                Catalyst Initiates Phase II Study for Pipeline Drug Firdapse

                by Zacks Equity Research

                Catalyst (CPRX) announces the initiation of phase II study to evaluate safety, tolerability and efficacy of its lead pipeline candidate, Firdapse.

                  Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease

                  by Zacks Equity Research

                  Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.

                    BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised

                    by Zacks Equity Research

                    BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017.

                      Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised

                      by Zacks Equity Research

                      Sarepta (SRPT) beat estimates on both counts in the third quarter of 2017 on strong sales of Exondys 51. Sarepta's pipeline candidate, golodirsen, shows potential.

                        What's in Store for BioMarin (BMRN) This Earnings Season?

                        by Zacks Equity Research

                        BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q3. However, slowdown in Federal purchasing orders in Brazil will hurt Naglazyme and Vimizim product revenues.

                          Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi

                          by Zacks Equity Research

                          Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi

                            Here's Why Sarepta Stock is Up More Than 60% So Far in 2017

                            by Zacks Equity Research

                            Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51's strong performance. The settlement of a patent litigation also boosted the stock.

                              Arpita Dutt headshot

                              Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

                              by Arpita Dutt

                              Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.

                                BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA

                                by Zacks Equity Research

                                The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.

                                  BioMarin Presents Interim Data on BMN 250 from Phase I/II

                                  by Zacks Equity Research

                                  BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.

                                    Sarepta's Golodirsen Positive in DMD Study, Shares Soar

                                    by Zacks Equity Research

                                    Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.

                                      BioMarin (BMRN) Up 2.5% Since Earnings Report: Can It Continue?

                                      by Zacks Equity Research

                                      BioMarin (BMRN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Stock Market News For August 31, 2017

                                        by Zacks Equity Research

                                        Stock market closed higher on Wednesday following a couple of bullish economic reports, even as the S&P 500 notched up a four-day winning streak.

                                          BioMarin (BMRN) in Focus: Stock Moves 5.6% Higher

                                          by Zacks Equity Research

                                          BioMarin (BMRN) shares rose nearly 6% in the last trading session, amid huge volumes.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update

                                            by Arpita Dutt

                                            It's all about CAR-T stocks this week with Gilead (GILD) announcing its intention to acquire Kite Pharma for $11.9 billion and Novartis gaining FDA approval for the first CAR-T cell therapy.

                                              BioMarin's Pegvaliase BLA Granted Priority Review by the FDA

                                              by Zacks Equity Research

                                              BioMarin Pharmaceutical (BMRN) announced that the FDA has accepted and granted priority review to the BLA for phenylketonuria candidate, Pegvaliase with a decision expected in February 2018.

                                                BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates

                                                by Zacks Equity Research

                                                BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.

                                                  Is Zoetis (ZTS) Poised for a Beat This Earnings Season?

                                                  by Zacks Equity Research

                                                  Zoetis, Inc. (ZTS) is expected to focus on performance of companion animal business during its second-quarter results.